The upregulation of immune checkpoints after photodynamic therapy reducing immune effect for treating breast cancer
Authors:
- 26 October 2023
- journal article
- research article
- Published by Springer Nature in Lasers in Medical Science
- Vol. 38 (1) , 1-11
Abstract
The immune effect induced by photodynamic therapy (PDT) has a limited effect on breast tumor. This study hypothesized that suppressive immune checkpoints on T cells might upregulate after PDT, which may reduce the antitumor effect of PDT for treating breast tumor. This study explored the alteration of immune checkpoint for the first time. A bilateral subcutaneous transplanted breast tumor mice model was established, and right tumors imitated primary tumors, and left tumors imitated distant tumors. Primary tumors were treated with PDT mediated by hematoporphyrin derivatives (HpD-PDT). Costimulatory molecules (ICOS, OX40, and 4-1BB) and immune checkpoints (PD1, LAG-3, CTLA-4, TIM-3, TIGIT) on tumor infiltrating T cells after HpD-PDT were analyzed by flow cytometry. Antitumor and immune effects were also assessed after HpD-PDT combined with anti-PD1 and LAG-3 antibodies. Primary tumors were suppressed, but distant tumors could not be inhibited after HpD-PDT. The number of T cells was increased, but function did not enhance after HpD-PDT. Additionally, costimulatory molecules (ICOS, OX40, and 4-1BB) were not elevated, but the suppressive immune checkpoints on tumor infiltrating T cells were upregulated after HpD-PDT. Notably, PD1+ LAG-3+ CD4+ T and PD1+ LAG-3+ CD8+ T cells were significantly increased. When PD1 and LAG-3 blockade combined with HpD-PDT, both primary and distant tumors were significantly suppressed, and antitumor immune effects were significantly enhanced. HpD-PDT could upregulate the PD1+ LAG-3+ CD4+ T and PD1+ LAG-3+ CD8+ T cells. Dual blockade of PD1 and LAG-3 immune checkpoints can enhance the antitumor effect of HpD-PDT.Keywords
Funding Information
- National Natural Science Foundation of China (61975239)
- Medical and Health Technology Innovation Project of the Chinese Academy of Medical Sciences (2019-I2M-5-061)
- Beijing Natural Science Foundation (7222174)
- Beijing Science and Technology New Star Program (Z211100002121168)
This publication has 27 references indexed in Scilit:
- Primary, Adaptive, and Acquired Resistance to Cancer ImmunotherapyCell, 2017
- Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell–driven rejection of high-grade gliomaScience Translational Medicine, 2016
- T-cell mediated anti-tumor immunity after photodynamic therapy: why does it not always work and how can we improve it?Photochemical & Photobiological Sciences, 2015
- Photodynamic Therapy and Cell Death Pathways2010
- PD-1 Is a Regulator of NY-ESO-1-Specific CD8+ T Cell Expansion in Melanoma PatientsThe Journal of Immunology, 2009
- The role of TNF superfamily members in T-cell function and diseasesNature Reviews Immunology, 2009
- Photodynamic therapy and anti-tumour immunityNature Reviews Cancer, 2006
- Fluence rate as a modulator of PDT mechanismsLasers in Surgery and Medicine, 2006
- Effect of Irradiation Fluence Rate on the Efficacy of Photodynamic Therapy and Tumor Oxygenation in Meta-Tetra (Hydroxyphenyl) Chlorin (mTHPC)-Sensitized HT29 Xenografts in Nude Mice1Radiation Research, 2002
- ICOS co-stimulatory receptor is essential for T-cell activation and functionNature, 2001